Skip to Main Content

Advertisement

Skip Nav Destination

Role of macrophage NOX2 in alveolar homeostasis, hydroxyurea versus peginterferon alfa-2a in high-risk PV and ET, and the emerging PV treatment landscape

In this week’s episode we’ll discuss an undescribed role for NOX2 in maintaining lung homeostasis through suppression of alveolar macrophage activation. We’ll also cover results of a phase 3 randomized trial that compares the safety and efficacy of hydroxyurea and peginterferon alfa-2a in patients with high-risk polycythemia vera and essential thrombocythemia (or PV and ET, respectively). Finally, we’ll go more in depth on the emerging treatment landscape for PV, and the limits of current clinical trial endpoints.


Released May 12, 2022

Subscribe today via iTunes   Google Play    Spotify to receive notification of each new episode as it's published.

 

The articles highlighted in this episode are listed below:

 
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X